Form 4: Immunome Inc. Director Wagenheim Acquires Stock Options
SEC Form 4 Filing
Director Philip Wagenheim of Immunome Inc. reports the acquisition of stock options.
Summary
- Philip Wagenheim, a director at Immunome Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of 11,333 stock options on June 13, 2024, at a price of $16.04.
- These options vest in four quarterly installments starting June 13, 2024, and expire on June 12, 2034.
- Following the transaction, Wagenheim directly owns 11,333 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a stock option grant, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of earliest transaction: acquisition of stock options. |
| 06/13/2024 | Options vest in 4 quarterly installments, commencing from this date. |
| 06/12/2034 | Expiration date of the stock options. |
| 06/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.